tradingkey.logo
搜尋

VolitionRX Ltd

VNRX
添加自選
2.000USD
-0.150-6.82%
收盤 05/15, 16:00美東報價延遲15分鐘
16.66M總市值
虧損本益比TTM

VolitionRX Ltd

2.000
-0.150-6.82%
查看詳細走勢圖
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-6.82%

5天

-11.11%

1月

-43.25%

6月

-69.80%

今年開始到現在

-60.88%

1年

-76.74%

TradingKey VolitionRX Ltd股票評分

單位: USD 更新時間: 2026-05-15

操作建議

VolitionRX Ltd當前公司基本面數據相對謹慎,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名135/382位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為29.21。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

VolitionRX Ltd評分

相關信息

行業排名
135 / 382
全市場排名
264 / 4482
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

VolitionRX Ltd亮點

亮點風險
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
業績高增長
公司營業收入穩步增長,連續3年增長122.80%
業績增長期
公司處於發展階段,最新年度總收入1.73M美元
估值高估
公司最新PE估值-0.46,處於3年歷史高位
機構減倉
最新機構持股1.13M股,環比減少15.69%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉1.26K股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.44

分析師目標

基於 5 分析師
買入
評級
29.207
目標均價
+1227.61%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

VolitionRX Ltd新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

VolitionRX Ltd簡介

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
公司代碼VNRX
公司VolitionRX Ltd
CEOButera (Salvatore Thomas)
網址https://volition.com/
KeyAI